Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Wed, 27.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has g [ … ]
Mon, 25.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
First efficacy data from the clinical trial with HDP-101 in multiple myeloma
Expansion of the ADC technology platform to include further payloads
New Management Board team
Successful financing activities; sales revenue and other i [ … ]
Tue, 19.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today ann [ … ]
Mon, 18.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5
Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms a [ … ]
Wed, 06.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its P [ … ]
Mon, 04.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx)
Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranche [ … ]
Wed, 29.11.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces Changes to the Executive Management Board
CEO Dr. Jan Schmidt-Brand to retire
His successor will be Prof. Dr. Andreas Pahl, Chief Scientific Officer
Ladenburg, Germany, 29 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Dr. Jan Schmidt-Brand, Chief Executive Officer (CEO) of Heidelb [ … ]
Wed, 15.11.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO). Site-specific AT [ … ]
Thu, 02.11.2023
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
Ladenburg, Germany, 2 November 2023 – Heidelberg Pharma AG (FSE: HPHA) will present new findings of its clinical Phase I/IIa study with the proprietary ADC candidate HDP-101 at the 65th Annual Meeting of the American Society o [ … ]
Thu, 12.10.2023
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
HDP-101 clinical trial in Europe and US continues with adjusted protocol and larger number of study sites in Europe; fifth patient cohort initiated at 100 µg/kg dosing
Patient from third cohort continues to be dosed and shows stable disease
Divestment of minorit [ … ]